Cardiff Oncology Inc (CRDF)
3.35
-0.11
(-3.18%)
USD |
NASDAQ |
May 23, 14:04
Cardiff Oncology Research and Development Expense (Quarterly): 8.008M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.008M |
| December 31, 2023 | 7.763M |
| September 30, 2023 | 8.022M |
| June 30, 2023 | 8.02M |
| March 31, 2023 | 9.052M |
| December 31, 2022 | 6.442M |
| September 30, 2022 | 6.009M |
| June 30, 2022 | 7.448M |
| March 31, 2022 | 7.208M |
| December 31, 2021 | 5.824M |
| September 30, 2021 | 4.154M |
| June 30, 2021 | 4.119M |
| March 31, 2021 | 3.279M |
| December 31, 2020 | 3.199M |
| September 30, 2020 | 2.855M |
| June 30, 2020 | 2.476M |
| March 31, 2020 | 2.706M |
| December 31, 2019 | 2.864M |
| September 30, 2019 | 2.819M |
| June 30, 2019 | 2.830M |
| March 31, 2019 | 2.649M |
| December 31, 2018 | 2.497M |
| September 30, 2018 | 1.830M |
| June 30, 2018 | 1.953M |
| March 31, 2018 | 1.884M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.206M |
| September 30, 2017 | 1.415M |
| June 30, 2017 | 0.9817M |
| March 31, 2017 | 4.280M |
| December 31, 2016 | 3.785M |
| September 30, 2016 | 3.937M |
| June 30, 2016 | 4.076M |
| March 31, 2016 | 3.208M |
| December 31, 2015 | 3.166M |
| September 30, 2015 | 2.546M |
| June 30, 2015 | 2.684M |
| March 31, 2015 | 2.198M |
| December 31, 2014 | 1.835M |
| September 30, 2014 | 1.990M |
| June 30, 2014 | 1.397M |
| March 31, 2014 | 1.442M |
| December 31, 2013 | 1.286M |
| September 30, 2013 | 0.9155M |
| June 30, 2013 | 0.9438M |
| March 31, 2013 | 0.8022M |
| December 31, 2012 | 0.5941M |
| September 30, 2012 | 0.5114M |
| June 30, 2012 | 0.4772M |
| March 31, 2012 | 0.3374M |
| December 31, 2011 | 0.3085M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.476M
Minimum
Jun 2020
9.052M
Maximum
Mar 2023
5.255M
Average
4.989M
Median
Research and Development Expense (Quarterly) Benchmarks
| BioVie Inc | 5.700M |
| Perspective Therapeutics Inc | 7.452M |
| Biolase Inc | 1.283M |
| Tenon Medical Inc | 0.669M |
| Adial Pharmaceuticals Inc | 0.4543M |